Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POMBILITI vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
500 mg orally twice daily
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Terminal elimination half-life is approximately 11 hours (range 6.5–19 h). Clinical context: supports twice-daily dosing with moderate accumulation; half-life prolonged in hepatic impairment.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Primarily metabolized by CYP3A4, CYP2C8, and CYP2C9; also undergoes glucuronidation. The active metabolite, GFT505, is formed via hydrolysis.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Primarily biliary-fecal (77% of absorbed dose) and renal (23% unchanged) with enterohepatic recirculation.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
>99% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 2000 L (>25 L/kg), indicating extensive extravascular distribution and tissue binding.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral bioavailability is approximately 25% (range 15–35%) due to first-pass metabolism; may increase with high-fat meal.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 250 mg twice daily; GFR <15 m L/min or dialysis: 250 mg once daily
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg twice daily; Child-Pugh C: not recommended
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Weight <40 kg: 10 mg/kg orally twice daily (max 500 mg/dose); Weight ≥40 kg: 500 mg twice daily
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
No specific adjustment required; monitor renal function and consider age-related decline in GFR
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
None.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Hepatotoxicity: Elevations in liver enzymes have been reported; monitor liver function tests before and during treatment.,Myopathy: Risk of muscle injury; assess creatine kinase if muscle symptoms occur.,Gallbladder-related events: Increased risk of cholelithiasis and cholecystitis.,Fetal risk: Based on animal data, may cause fetal harm; advise effective contraception in females of reproductive potential.,Renal impairment: Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²).
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Hypersensitivity to elafibranor or any component of the formulation.,Severe hepatic impairment (Child-Pugh class C).
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
No known food interactions. Maintain a balanced diet as recommended by a healthcare provider. There are no specific dietary restrictions required with Pombiliti.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show embryolethality and teratogenicity at subclinical doses.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
No data on presence in human milk; M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression, myelosuppression), breastfeeding is not recommended during therapy and for at least 3 months after last dose.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
No dose adjustment recommendations are possible; Pombiliti is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not studied due to contraindication. No specific dosing guidelines exist for pregnant patients.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
Pombiliti (cipaglucosidase alfa) is a recombinant human acid alpha-glucosidase (GAA) enzyme replacement therapy for Pompe disease. Do not confuse with alglucosidase alfa (Myozyme/Lumizyme). Requires premedication with antihistamines and antipyretics due to risk of infusion-associated reactions (IARs). Monitor for anaphylaxis, particularly during initial infusions. Administer by IV infusion over approximately 4 hours. Use a low-protein-binding infusion set with an in-line low-protein-binding filter. May cause rapid deterioration in patients with cardiac hypertrophy; monitor cardiac function before and during treatment.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Inform your healthcare provider immediately if you experience hives, itching, difficulty breathing, swelling, chest tightness, or fever during or after the infusion.,You may receive premedications (such as antihistamines and acetaminophen) before your infusion to reduce the risk of allergic reactions.,Do not miss your scheduled infusions; regular treatment is necessary to manage Pompe disease.,Report any new or worsening muscle weakness, breathing difficulties, or heart-related symptoms.,Keep a list of all medications you take, including over-the-counter drugs and supplements, and share it with your doctor.,Pombiliti is not a cure; it is an enzyme replacement therapy to reduce symptoms and slow disease progression.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POMBILITI vs ADDERALL 30, answered by our medical review team.
POMBILITI is a Immunomodulatory Agent that works by POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POMBILITI and ADDERALL 30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POMBILITI is: 500 mg orally twice daily. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POMBILITI and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POMBILITI is classified as Category C. Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third . ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.